Paper Details
- Home
- Paper Details
Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus.
Author: EifaAberash, GutemaSelamawit, HirigoAgete Tadewos, KetemaWorku
Original Abstract of the Article :
HIV-infected people have started to live longer since the introduction of antiretroviral therapy, however various co-morbid illnesses have emerged. Three HIV-infected individuals, all at least 43 years old, reported with a new onset of type 2 diabetes after switching to dolutegravir-combined antiret...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874156/
データ提供:米国国立医学図書館(NLM)
Dolutegravir-Based Antiretroviral Therapy: Potential Risks of Diabetes
Dolutegravir is a powerful antiretroviral medication used to treat HIV infection. This study investigates the potential association between dolutegravir-based therapy and the development of diabetes mellitus in HIV-infected individuals. The study reports three cases of individuals who developed type 2 diabetes after switching to dolutegravir-based regimens.
Dolutegravir and Hyperglycemia: A Potential Side Effect
The study's findings suggest a possible link between dolutegravir-based therapy and the development of hyperglycemia and other diabetes-related side effects. While the cases presented in this study do not definitively prove a causal relationship, they highlight the need for caution and careful monitoring of blood glucose levels in individuals receiving dolutegravir-based therapy, particularly those with existing risk factors for diabetes.
The Importance of Vigilance and Personalized Care in HIV Treatment
This study emphasizes the importance of comprehensive monitoring and personalized care for individuals living with HIV, particularly those receiving dolutegravir-based treatment. Regular blood glucose monitoring, along with proactive management of diabetes risk factors, is crucial for ensuring optimal treatment outcomes and minimizing potential complications associated with dolutegravir therapy.
Dr. Camel's Conclusion
Just as a camel adapts to the harsh desert environment, individuals living with HIV must navigate the complexities of treatment and potential side effects. This study serves as a reminder that vigilant monitoring and personalized care are essential for ensuring the safety and effectiveness of antiretroviral therapy, including dolutegravir-based regimens.
Date :
- Date Completed n.d.
- Date Revised 2022-03-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.